ZIVOW — Zivo Bioscience, Inc.

OTC · Health Care · Biotechnology · CIK 1101026 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 65,625 21,288 -1,018,343 -1,033,056 559,452 57,222 3,846,055
Jun 2025 53,400 17,922 -1,632,872 -1,640,232 703,327 9,823 3,244,073
Mar 2025 0 0 -4,208,788 -4,211,188 1,331,334 517,189 2,948,613
Dec 2024 90,000 27,000 -1,596,419 -1,601,385 1,643,122 1,542,442 2,158,019

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,078,926
Investing CF
$0
Financing CF
$2,976,745
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-143,851,025
Inventory
Receivables
$0
ST Investments
EBIT TTM
$-8,458,176
Pretax Income TTM
$-8,485,861
Interest Exp TTM
$27,685
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$209,025
EBITDA
Free Cash Flow
$-2,617,243
Enterprise Value
Total Cash
$57,222
Total Debt
$819,695
Shares Out
Trailing EPS
Book Value
$-0.86
ROE
ROA
-1001.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 157,220 -13,361,897 -13,384,836 1,643,122 2,158,019 -4,313,510
Dec 2023 27,650 -7,263,012 -7,777,184 555,715 2,761,558 -5,799,893
Dec 2022 0 -8,731,974 -8,745,293 2,123,019 2,133,641 -7,102,612
Dec 2021 0 -8,645,119 -8,755,881 8,990,178 2,947,969 -6,803,333

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $181.31B $335.94
GILD GILEAD SCIENCES, INC. $166.04B $133.73
ARGX ARGENX SE $50.27B $808.43
RVMD Revolution Medicines, Inc. $32.93B $154.89
BIIB BIOGEN INC. $28.51B $193.08

News headlines (Yahoo Finance, 1h cache)

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
2026-05-12 14:09 · Yahoo
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
2026-04-06 12:00 · Yahoo
ZIVO Bioscience Provides Special Letter to Shareholders
2026-03-27 20:43 · Yahoo
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
2025-09-10 12:30 · Yahoo
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
2025-06-20 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.